India clears major milestone in cervical cancer fight with validation of first indigenous HPV DNA test

Cervical cancer remains one of the leading causes of cancer deaths among women in India

India validates first indigenous HPV DNA test for cervical cancer screening

Molbio Diagnostics' Truenat HPV-HR Plus becomes the world's first formally validated reduced-valency HPV test, meeting WHO-IARC standards

MSD launches cervical cancer awareness campaign with Madhuri Dixit Nene

The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness

Cbio launches first-in-human trial for groundbreaking cervical cancer therapy

Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening

Hologic has been at the forefront of cervical cancer screening for decades

10.18 Cr women screened for cervical cancer under Govt. schemes

This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases

WHO endorses Roche’s dual-stain cytology testing in its cervical cancer prevention guidelines

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results

FDA grants full approval for TIVDAK to treat cervical cancer

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer

USFDA approves Merck’s Keytruda plus chemoradiotherapy with FIGO 2014 stage III-IVA cervical cancer

Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients

USFDA accepts sBLA of TIVDAK for priority review for patients with metastatic cervical cancer

Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy